Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.

PubWeight™: 1.28‹?› | Rank: Top 10%

🔗 View Article (PMC 2118550)

Published in J Exp Med on April 02, 2007


Stefanie Loeser1, Karin Loser, Martijn S Bijker, Manu Rangachari, Sjoerd H van der Burg, Teiji Wada, Stefan Beissert, Cornelis J M Melief, Josef M Penninger

Author Affiliations

1: Institute of Molecular Biotechnology, Austrian Academy of Science, 1030 Vienna, Austria.

Articles citing this

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature (2014) 3.45

Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05

RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer (2011) 2.06

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med (2009) 1.78

Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity (2010) 1.25

Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res (2013) 1.16

Annular PIP3 accumulation controls actin architecture and modulates cytotoxicity at the immunological synapse. J Exp Med (2013) 1.09

Decreased diacylglycerol metabolism enhances ERK activation and augments CD8+ T cell functional responses. J Biol Chem (2010) 1.09

Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res (2012) 1.06

Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice. J Clin Invest (2010) 1.02

Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proc Natl Acad Sci U S A (2010) 1.01

Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol Med (2013) 0.99

Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment. Clin Cancer Res (2014) 0.90

An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol (2007) 0.89

Cbl-b and itch: key regulators of peripheral T-cell tolerance. Cancer Res (2010) 0.88

Cbl-b in T-cell activation. Semin Immunopathol (2010) 0.88

Cbl exposes its RING finger. Nat Struct Mol Biol (2012) 0.87

Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS One (2012) 0.87

E3 ubiquitin ligase Cbl-b in innate and adaptive immunity. Cell Cycle (2014) 0.86

Diacylglycerol kinase α establishes T cell polarity by shaping diacylglycerol accumulation at the immunological synapse. Sci Signal (2014) 0.85

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches. Front Immunol (2016) 0.84

Releasing the brake: targeting Cbl-b to enhance lymphocyte effector functions. Clin Dev Immunol (2012) 0.84

Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression. Front Immunol (2016) 0.83

Indispensable roles of mammalian Cbl family proteins as negative regulators of protein tyrosine kinase signaling: Insights from in vivo models. Commun Integr Biol (2011) 0.82

Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. Front Oncol (2015) 0.81

Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response. Cancer Immunol Immunother (2009) 0.80

T-cell tolerance in cancer. Immunotherapy (2013) 0.79

The role of the e3 ligase cbl-B in murine dendritic cells. PLoS One (2013) 0.79

Engineering effective T-cell based antitumor immunity. Oncoimmunology (2013) 0.76

Cbl-b: Roles in T Cell Tolerance, Proallergic T Cell Development, and Cancer Immunity. Inflamm Cell Signal (2015) 0.75

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation. Front Immunol (2017) 0.75

Absence of Grail promotes CD8(+) T cell anti-tumour activity. Nat Commun (2017) 0.75

Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition. Oncotarget (2017) 0.75

Articles cited by this

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71

The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09

Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta (1996) 7.79

Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77

The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53

Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28

Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol (2004) 4.21

Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol (2001) 4.11

Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08

Cbl-b regulates the CD28 dependence of T-cell activation. Nature (2000) 3.89

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73

Does the immune system see tumors as foreign or self? Annu Rev Immunol (2001) 3.71

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77

Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med (1997) 2.47

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med (1997) 1.96

TCR affinity and negative regulation limit autoimmunity. Nat Med (2004) 1.94

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93

Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87

Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res (1977) 1.82

Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol (2006) 1.62

Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. J Immunol (2004) 1.50

Strategies for immunotherapy of cancer. Adv Immunol (2000) 1.36

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res (2006) 1.23

Vaccination for treatment and prevention of cancer in animal models. Adv Immunol (2006) 1.11

Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol (2004) 1.10

Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. J Immunol (2005) 0.96

Environmental factors in nonmelanoma and melanoma skin cancer. J Epidemiol (1999) 0.95

New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol (1993) 0.94

Reduced ultraviolet-induced carcinogenesis in mice with a functional disruption in B7-mediated costimulation. J Immunol (1999) 0.93

The role of B7-CD28 co-stimulation in tumor rejection. Int Immunol (1998) 0.84

Use of mutant mice in photoimmunological and photocarcinogenic investigations. Methods (2002) 0.79

Articles by these authors

Cerebral organoids model human brain development and microcephaly. Nature (2013) 9.07

Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66

Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27

Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02

Mitogen-activated protein kinases in apoptosis regulation. Oncogene (2004) 4.76

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 4.35

Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28

The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol (2007) 4.12

Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature (2006) 4.09

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01

Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82

Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 3.74

Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol (2003) 3.73

RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med (2005) 3.68

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 3.46

Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity (2003) 3.36

RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol (2001) 3.27

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med (2005) 3.26

The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19

AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19

Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol (2006) 3.19

Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature (2005) 3.09

Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93

RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med (2007) 2.91

Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell (2010) 2.91

The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol (2004) 2.90

Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol (2004) 2.82

The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity (2008) 2.81

Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76

Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell (2011) 2.69

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68

Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest (2003) 2.68

The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity (2003) 2.67

The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity (2008) 2.57

ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature (2012) 2.53

Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol (2012) 2.49

The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47

Genome-wide RNAi screen identifies genes involved in intestinal pathogenic bacterial infection. Science (2009) 2.47

Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39

T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med (2006) 2.38

A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell (2010) 2.37

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

A global in vivo Drosophila RNAi screen identifies NOT3 as a conserved regulator of heart function. Cell (2010) 2.27

Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood (2007) 2.21

Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke (2012) 2.18

RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci (2008) 2.10

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med (2003) 2.04

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04

M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int (2008) 1.99

MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98

High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96

Rank signaling links the development of invariant γδ T cell progenitors and Aire(+) medullary epithelium. Immunity (2012) 1.94

TCR affinity and negative regulation limit autoimmunity. Nat Med (2004) 1.94

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90

Dexras1 potentiates photic and suppresses nonphotic responses of the circadian clock. Neuron (2004) 1.89

Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology (2009) 1.83

Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med (2011) 1.79

Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78

Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res (2009) 1.78

Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. Immunity (2002) 1.77

Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation (2010) 1.77

High precision quantitative proteomics using iTRAQ on an LTQ Orbitrap: a new mass spectrometric method combining the benefits of all. J Proteome Res (2009) 1.75

Lineage-committed osteoclast precursors circulate in blood and settle down into bone. J Bone Miner Res (2011) 1.74

Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res (2007) 1.74

Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. Circ Res (2006) 1.71

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med (2010) 1.70

AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene (2004) 1.68

Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol (2006) 1.67

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell (2012) 1.65